ABVX.PA · ABIVAX Société Anonyme

-

Please sign in to comment on ABVX.PA

1 Comment

Admin

4 years, 1 month ago

ABIVAX Société Anonyme is currently in a long term uptrend where the price is trading 15.6% above its 200 day moving average.

From a valuation standpoint, the stock is 3733.7% more expensive than other stocks from the Healthcare sector with a price to sales ratio of 10480.4.

ABIVAX Société Anonyme's total revenue sank by 0.0% to $20K since the same quarter in the previous year.

Its net income has dropped by 0.0% to $-8M since the same quarter in the previous year.

Finally, its free cash flow grew by 47.7% to $-4M since the same quarter in the previous year.

Based on the above factors, ABIVAX Société Anonyme gets an overall score of 2/5.

Exchange	PA
CurrencyCode	EUR
ISIN	FR0012333284
Industry	Biotechnology
Sector	Healthcare

Target Price	25.425
PE Ratio	None
Market Cap	401M
Beta	1.58
Dividend Yield	None

ABOUT

ABIVAX Société Anonyme

ABIVAX Société Anonyme, a clinical-stage biotechnology company, focuses on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Its lead drug candidate includes obefazimod that is in Phase 3 clinical trials for the treatment of adults with moderately to severely active ulcerative colitis, as well as in Phase 2b clinical trial to treat patients with Crohn's disease. The company was incorporated in 2013 and is headquartered in Paris, France.

ABVX.PA · ABIVAX Société Anonyme

-

ABIVAX Société Anonyme

Earnings

Valuation

Cash Flow

Profitability

Performance

Backtest ABIVAX Société Anonyme using a moving average strategy